Integrated Biology Platform
Delivering comprehensive solutions from early discovery through IND-enabling translational studies
Functional Assays
Functional Assays
Comprehensive phenotypic and patient-relevant assay platforms spanning enzyme-level biochemical readouts to complex patient-derived organoid systems. Applied across both oncology and immunology research programs.
Enzyme-Based Assays
- Enzymatic activity and inhibition assays with fluorescence, luminescence, and absorbance readouts
- Multi-readout biochemical platforms: FP, AlphaLISA, HTRF, pull-down, and SEC-based methods
- Full kinase profiling panels covering 79 to 364 members, including resistance mutant coverage
- Customized assay development for novel or non-standard enzyme targets
Cell-Based Assays
Standard cell-based readouts
- Cell proliferation and cytotoxicity (CTG, resazurin, and luminescent platforms)
- Apoptosis analysis: Annexin V, caspase activation, sub-G1 DNA content
- Cell cycle profiling by flow cytometry
- Drug combination and synergy evaluation (Loewe, Bliss, and HSA synergy models)
Advanced 3D culture systems
- 3D tumor spheroid formation and growth inhibition assays
- Cell migration, invasion, and colony formation assays
- Advanced co-culture and tumor microenvironment modeling systems
PBMC & Blood-Based Assays
Clinical sample resources
- Fresh human whole blood and PBMCs from healthy donors and patients (IRB-compliant, consented collection)
- Broad disease coverage: RA, SLE, IBD, Psoriasis, Atopic Dermatitis, Ankylosing Spondylitis, and more
Immune function assays (100+ validated assays)
- Immune cell activation: T cells, B cells, NK cells, and basophils
- T cell differentiation assays: Th1/Th2/Th17/Treg polarization
- Cytotoxicity assays: ADCC, CDC, and T cell-mediated killing
- Cytokine release assays in whole blood and PBMC systems
- Inflammasome activation assays: NLRP3, AIM2, NLRC4
- Intracellular signaling: phospho-flow cytometry and pathway analysis
Patient-Derived Cell & Organoid-Based Assays
Patent-derived cell (PDC) assays
- 150+ PDC models — rapid primary tumor cell isolation and expansion
- Drug sensitivity and response profiling in patient-relevant primary cell systems
- Biomarker discovery and patient stratification strategies
Patent-derived organoid (PDO) assays
- 1,600+ PDO models across gastrointestinal, lung, breast, hematological, and other malignancies
- High-throughput phenotypic screening on organoids with preserved tumor architecture
- Culture condition optimization to maintain tumor heterogeneity and growth dynamics
- Comprehensive pathological and molecular validation of all PDO models
Tumor-immune co-culture systems
- Tumor organoid–immune cell co-culture reconstitution in vitro
- Immune-mediated tumor killing and response measurement assays
- Evaluation of checkpoint inhibitors and immune modulators in co-culture
- Mechanistic studies of tumor–immune microenvironment interactions
Reprogramming Cells, Empowering Medicine
©2026 PRECEDO Biotechnology Co., Ltd. Powered by：www.300.cn